Portage Biotech Inc Stock Price, News & Analysis

Welcome to our dedicated page for Portage Biotech news (Ticker: PRTG), a resource for investors and traders seeking the latest updates and insights on Portage Biotech stock.

The PRTG news page on Stock Titan provides an archive of disclosures and press releases for Portage Biotech Inc., now renamed AlphaTON Capital Corp. Company communications describe a transition from being solely a clinical-stage immuno-oncology company to operating with two primary business lines: a legacy oncology research and development portfolio and a new digital asset treasury strategy centered on The Open Network (TON) token and the Telegram ecosystem.

News items associated with the former PRTG symbol include updates on clinical and preclinical programs such as PORT-6, a highly selective A2A adenosine receptor antagonist, and PORT-7, a selective A2B adenosine receptor inhibitor. Press releases report confirmatory and promising preclinical data in mesothelioma models, plans to commence first-in-human trials for PORT-7, and the resumption of enrollment in the final dose-escalation cohort for PORT-6 in the ADPORT-601 Phase 1b trial. Additional oncology-related news covers the re-launch of the adenosine-focused subsidiary as Cyncado Therapeutics and strategic transactions such as a stock-for-stock exchange with Compedica Holdings Limited.

Filings and press releases also describe capital markets developments, including private financings, at-the-market offering agreements, and Nasdaq listing compliance updates. More recent news under the company’s new name, AlphaTON Capital Corp, focuses on the launch of a TON digital asset treasury strategy, a significant private placement involving both cash and cryptocurrency, and loan and treasury management agreements intended to support large-scale TON acquisitions and management.

Investors and researchers can use this page to review how the business mix, financing activities, and strategic direction have evolved from Portage Biotech’s immuno-oncology focus under PRTG to AlphaTON Capital Corp’s combined digital asset and legacy oncology strategy associated with the ATON ticker.